Northeast Investment Management Has $2.90 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Northeast Investment Management lessened its position in Pfizer Inc. (NYSE:PFE) by 5.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,099 shares of the biopharmaceutical company’s stock after selling 5,459 shares during the period. Northeast Investment Management’s holdings in Pfizer were worth $2,897,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Citizens National Bank Trust Department increased its holdings in Pfizer by 11.3% in the 3rd quarter. Citizens National Bank Trust Department now owns 52,769 shares of the biopharmaceutical company’s stock worth $1,527,000 after purchasing an additional 5,355 shares in the last quarter. Kanawha Capital Management LLC increased its holdings in Pfizer by 3.3% in the 3rd quarter. Kanawha Capital Management LLC now owns 279,327 shares of the biopharmaceutical company’s stock worth $8,084,000 after purchasing an additional 8,975 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in Pfizer by 120.7% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 4,498,313 shares of the biopharmaceutical company’s stock worth $130,181,000 after purchasing an additional 2,459,666 shares in the last quarter. Harbour Investment Management LLC grew its position in shares of Pfizer by 1.9% in the 3rd quarter. Harbour Investment Management LLC now owns 34,950 shares of the biopharmaceutical company’s stock valued at $1,011,000 after buying an additional 660 shares during the last quarter. Finally, TrueWealth Advisors LLC grew its position in shares of Pfizer by 2.7% in the 3rd quarter. TrueWealth Advisors LLC now owns 18,699 shares of the biopharmaceutical company’s stock valued at $541,000 after buying an additional 490 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several research analyst reports. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Citigroup assumed coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. UBS Group raised their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $28.09 on Monday. The business’s fifty day simple moving average is $29.03 and its 200 day simple moving average is $28.62. The firm has a market capitalization of $159.18 billion, a P/E ratio of 37.96, a price-to-earnings-growth ratio of 0.90 and a beta of 0.67. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the company posted ($0.17) earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.98%. Pfizer’s payout ratio is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.